CanSino Biologics Gets NMPA Nod to Review Supplemental Application Expanding Menhycia® Age Range

Bulletin Express07-19

CanSino Biologics Inc. announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s supplemental drug application to broaden the indicated age range of its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®. The proposed label expansion would extend coverage from the current “3 months to 6 years (83 months)” to “3 months to 17 years,” positioning the product for use across the entire pediatric and adolescent population.

Menhycia®, approved for commercialization in December 2021 as China’s first quadrivalent meningococcal conjugate vaccine (MCV4), initially covered children aged 3 months to 6 years. The label was first broadened in February 2026 to include all children up to 83 months. According to the company, the vaccine has narrowed the gap with comparable offerings in developed markets and has delivered a steady increase in domestic market share since launch.

CanSino Biologics views the latest regulatory milestone as an opportunity to address unmet demand for high-end meningococcal vaccines among older children and teenagers in China. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179362938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-19 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179362938","market":"hk","top_or_hot":-1,"title":"CanSino Biologics Gets NMPA Nod to Review Supplemental Application Expanding Menhycia® Age Range","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s supplemental drug application to broaden the indicated age range of its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®. The proposed label expansion would extend coverage from the current “3 months to 6 years (83 months)” to “3 months to 17 years,” positioning the product for use across the entire pediatric and adolescent population.</p>\n<p>Menhycia®, approved for commercialization in December 2021 as China’s first quadrivalent meningococcal conjugate vaccine (MCV4), initially covered children aged 3 months to 6 years. The label was first broadened in February 2026 to include all children up to 83 months. According to the company, the vaccine has narrowed the gap with comparable offerings in developed markets and has delivered a steady increase in domestic market share since launch.</p>\n<p>CanSino Biologics views the latest regulatory milestone as an opportunity to address unmet demand for high-end meningococcal vaccines among older children and teenagers in China. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics Gets NMPA Nod to Review Supplemental Application Expanding Menhycia® Age Range</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics Gets NMPA Nod to Review Supplemental Application Expanding Menhycia® Age Range\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-19 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s supplemental drug application to broaden the indicated age range of its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®. The proposed label expansion would extend coverage from the current “3 months to 6 years (83 months)” to “3 months to 17 years,” positioning the product for use across the entire pediatric and adolescent population.</p>\n<p>Menhycia®, approved for commercialization in December 2021 as China’s first quadrivalent meningococcal conjugate vaccine (MCV4), initially covered children aged 3 months to 6 years. The label was first broadened in February 2026 to include all children up to 83 months. According to the company, the vaccine has narrowed the gap with comparable offerings in developed markets and has delivered a steady increase in domestic market share since launch.</p>\n<p>CanSino Biologics views the latest regulatory milestone as an opportunity to address unmet demand for high-end meningococcal vaccines among older children and teenagers in China. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1179362938","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179362938","pubTimestamp":1784456504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s supplemental drug application to broaden the indicated age range of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物获得 NMPA 批准审查扩大 Menhycia 的补充申请®年龄范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s supplemental drug application to broaden the indicated age range of its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®. The proposed label expansion would extend coverage from the current “3 months to 6 years (83 months)” to “3 months to 17 years,” positioning the product for use across the entire pediatric and adolescent population.\nMenhycia®, approved for commercialization in December 2021 as China’s first quadrivalent meningococcal conjugate vaccine (MCV4), initially covered children aged 3 months to 6 years. The label was first broadened in February 2026 to include all children up to 83 months. According to the company, the vaccine has narrowed the gap with comparable offerings in developed markets and has delivered a steady increase in domestic market share since launch.\nCanSino Biologics views the latest regulatory milestone as an opportunity to address unmet demand for high-end meningococcal vaccines among older children and teenagers in China. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179362938","isCrawlerRequest":true}